FLT3 and acute myeloid leukemia: Moreover, ACS reduced cell viability of primary AML samples carrying FLT3 (Fig. 5E, G) or RAS (Fig. 5F, H) mutations and accentuated the leukemia inhibitory and apoptotic effects of quizartinib, ibrutinib, and doxorubicin.